Biohaven Ltd.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
BHVN$15.23+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Operating expenses: | |||
| Research and development | $635,065 | $795,871 | $373,281 |
| General and administrative | 110,313 | 89,240 | 62,770 |
| Total operating expenses | 745,378 | 885,111 | 436,051 |
| Loss from operations | (745,378) | (885,111) | (436,051) |
| Other income: | |||
| Other income, net | 7,998 | 39,424 | 26,500 |
| Total other income, net | 7,998 | 39,424 | 26,500 |
| Loss before provision (benefit) for income taxes | (737,380) | (845,687) | (409,551) |
| Provision (benefit) for income taxes | 1,442 | 735 | (1,383) |
| Net loss | $(738,822) | $(846,422) | $(408,168) |
| Net loss per share — basic and diluted | $(6.86) | $(9.28) | $(5.73) |
| Weighted average common shares outstanding—basic and diluted | 107,624,885 | 91,234,337 | 71,200,527 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.